BRIEF — Vanda Pharmaceuticals Provides Update On Vqw — 765 Clinical Development Program

Oct 14 (Reuters) — Vanda Pharmaceuticals Inc: Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program Vanda Pharmaceuticals - Phase Iii Study Of Vqw-765 Did Not Meet Primary Endpoint In Social Anxiety Disorder Vanda Pharmaceuticals - Vqw-765 Found Safe And Well Tolerated In Phase Iii Study Vanda Pharmaceuticals - Phase Iii Study Did Not Meet Key Secondary Endpoint In Full Population Vanda Pharmaceuticals - Vqw-765 Program On Hold Pending Further Analysis Source text:... Further company coverage: VNDA.O (((Reuters.Briefs@thomsonreuters.com;));)